Jay Strum - G1 Therapeutics Chief Scientific Officer
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
Executive
Dr. Jay C. Strum Ph.D. is the Chief Scientific Officer of G1 Therapeutics Inc. Dr. Strum has served as our Chief Scientific Officer since 2009, and in addition to this role, served as our President and a member of our board of directors from 2011 until 2014. Prior to joining us, Dr. Strum served as a scientist, manager and then Director of the Genomics Division at GlaxoSmithKline plc, or GSK, a British pharmaceutical company, from May 1995 to February 2009, where he developed drugs in multiple therapeutic areas and target classes with a focus on kinases. In his role as a manager at GSK, Dr. Strum served as a program leader of interdisciplinary research and development teams in early drug discovery in metabolic diseases and oncology, and he contributed to the discovery of numerous drug candidates and the development of three approved drugs, including TYKERB. As the Director of the Genomics Division at GSK, he led the creation and operation of an international department responsible for supporting genomics research in all therapeutic areas within GSK. Dr. Strum is the author of more than 40 scientific publications and coinventor of all intellectual property owned or coowned by the Company that covers trilaciclib or G1T38 or their method of use, which consists of 11 patent families with five issued U.S. patents. Dr. Strum is also the coinventor of another six patent families and six issued patents that cover additional compounds of interest. In total, Dr. Strum is a coinventor of more than 75 applications that have entered the national phase of prosecution in countries outside the United States since 2016.
| Age | 60 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 919 213 9835 |
| Web | https://www.g1therapeutics.com |
G1 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.192) % which means that it has lost $0.192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0901) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.G1 Therapeutics currently holds 57.17 M in liabilities with Debt to Equity (D/E) ratio of 1.24, which is about average as compared to similar companies. G1 Therapeutics has a current ratio of 4.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about G1 Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jennifer Jarrett | Arcus Biosciences | 50 | |
| Barbara Hickingbottom | Fate Therapeutics | N/A | |
| Sunil PharmD | Annexon | N/A | |
| Stephen Young | Arcus Biosciences | 55 | |
| Edward Rebar | Sana Biotechnology | 56 | |
| Stephanie CLP | Sangamo Therapeutics | N/A | |
| Robert Sullivan | Heron Therapeuti | 46 | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| John MD | Sana Biotechnology | N/A | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
| Jim MBA | Fate Therapeutics | N/A | |
| Ezio MD | MacroGenics | 70 | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Susan Lundeen | Allogene Therapeutics | 58 | |
| Spencer JD | PDS Biotechnology Corp | 54 | |
| Cindy Tahl | Fate Therapeutics | 51 | |
| David Ojala | Sangamo Therapeutics | N/A | |
| Yinlin Chen | Allogene Therapeutics | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Reigin Zawadzki | Caribou Biosciences | N/A | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 |
G1 Therapeutics Leadership Team
Elected by the shareholders, the G1 Therapeutics' board of directors comprises two types of representatives: G1 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GTHX. The board's role is to monitor G1 Therapeutics' management team and ensure that shareholders' interests are well served. G1 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, G1 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monica Thomas, General Officer | ||
| Jay Strum, Chief Scientific Officer | ||
| Andrew Perry, Chief Officer | ||
| Jeff Macdonald, Head of Investor Relations/Public Relations | ||
| Jennifer CPA, Chief Officer | ||
| Alexander MS, VP Operations | ||
| John V, Chief Officer | ||
| ChB MB, Chief RD | ||
| Terry MSc, Chief Officer | ||
| John Bailey, President CEO | ||
| William Roberts, Vice Communications | ||
| Mark Avagliano, Chief Officer | ||
| Evan MBA, Vice Marketing | ||
| Terry Murdock, Senior Vice President - Development Operations |
GTHX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is G1 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Shares Owned By Insiders | 10.92 % | |||
| Shares Owned By Institutions | 54.61 % | |||
| Number Of Shares Shorted | 3.41 M | |||
| Price To Earning | (1.95) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |